LivaNova (NASDAQ:LIVN) Releases Earnings Results, Beats Estimates By $0.28 EPS

LivaNova (NASDAQ:LIVN) released its earnings results on Wednesday. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28, Briefing.com reports. The company had revenue of $294.90 million for the quarter, compared to the consensus estimate of $278.17 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. LivaNova’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 earnings per share. LivaNova updated its FY 2024 guidance to 3.050-3.150 EPS and its FY24 guidance to $3.05-3.15 EPS.

LivaNova Stock Down 0.2 %

Shares of NASDAQ LIVN traded down $0.14 during midday trading on Thursday, hitting $62.48. 981,429 shares of the company’s stock were exchanged, compared to its average volume of 642,266. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. LivaNova has a twelve month low of $42.75 and a twelve month high of $63.21. The company has a market cap of $3.38 billion, a PE ratio of 195.69 and a beta of 0.92. The firm’s fifty day simple moving average is $54.44 and its 200-day simple moving average is $50.85.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Mizuho increased their price objective on LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday. StockNews.com upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Barclays increased their price objective on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Robert W. Baird raised their target price on LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research note on Wednesday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $66.20.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.